NEWS
< back to news list

NanoGroup raised PLN 4.7 million from the issue of L and M1 shares

As a result of the subscription of L-series shares and M1-series shares carried out in May, NanoGroup concluded share subscription agreements for a total issue price of PLN 4.7 million, the company said. The funds raised will fund the next stage of research and development of the NanOX system, which is a device and NanOX fluid for extracorporeal storage of organs for transplantation.

“May’s fully successful share issuance is one element of the implementation of a broad plan to raise financing to enable NanoGroup to intensify its R&D work, particularly in the development of the Nanosanguis-led project, the NanOX system. As stipulated in a separate investment agreement with eCapital Sp. z o.o. owned by Mr. Michal Lach, the next phases of the project’s development, and thus the possibility of raising additional funds, have been scheduled until the end of 2025. The total value of the financing we can raise as a result of the activities undertaken in recent months is nearly PLN 10 million, and our further plans include. Obtaining research and development funding from EU funds. We are confident that all these activities will result in bringing the project to the phase I clinical trial stage, and will also enable intensification of activities related to acquiring an industry partner,” said CEO Przemyslaw Mazurek, quoted in the release.

NanoGroup carried out a subscription for series L ordinary bearer shares. The subscription included 3,699,490 securities. Share subscription agreements have been executed for all of them and all shares have been paid for. The issue value of the shares was PLN 3,699,490. Also issued were 952,381 series M1 shares for PLN 1 million. As a result of the issues, NanoGroup raised nearly PLN 4.7 million, it recalled.

The NanOX project, being developed by subsidiary Nanosanguis, is a proprietary system consisting of a specialized NanOX Recovery Box and NanOX perfusion fluid, which is used for extracorporeal storage of organs for transplantation. Current work is focused on performing a successful autotransplantation of a pig kidney.

NanoGroup is a commercial research organization, formed as a result of the combination of a team of professionals from the fields of biotechnology, medicine and business. The company was established in 2016 to consolidate into a single group of special-purpose companies with projects centered around nanotechnology. In 2017, the company debuted on the WSE.

Read more on the topic in: ibiznes, stooq, banker.

Copyright © NanoGroup 2024

Prof. Tomasz Ciach

Founder, Member of the Management Board of NANOGROUP S.A.

Nanotechnology expert. Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). Work on various aspects of Biomedical Engineering, mostly on biomedical nanotechnology, active coatings for medical implants, nanoparticles for cancer treatment, biodegradable and nonbiodegradable implants, bone and vascular prosthesis. He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Piotr Mierzejewski

Vice President of the Management Board of NANOGROUP S.A.

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.